anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: I. Estimate the maximum tolerated dose of total bone marrow irradiation (TMI) that can be administered as planned consolidation utilizing autologous peripheral blood stem cell support following local radiotherapy (if indicated) and prior busulfan, melphalan, and thiotepa. II. Examine the efficacy of this dual transplant approach for high-risk patients with Ewing's sarcoma, peripheral primitive neuroectodermal tumor, or rhabdomyosarcoma in first complete remission or greater.

OUTLINE: This is a two part, radiation dose escalation study. Peripheral blood stem cells (PBSC) are collected after 5-6 daily injections of G-CSF. The PBSC are infused in two halves. One half is given after chemotherapy and the other half after total marrow irradiation (TMI). Transplant #1 (part one) consists of chemotherapy and PBSC infusion. Busulfan (BU) is administered orally every 6 hours for 3 days for a total of 12 doses on days -8, -7 and -6. Melphalan is intravenously infused over 30 minutes for 2 days on days -5 and -4. Thiotepa is intravenously infused over 2 hours on days -3 and -2. PBSC are infused on day 0, 36-48 hours after completion of chemotherapy. Patients are considered for local irradiation therapy between transplant #1 and #2 if tissue limiting irradiation doses to bulk tumor site have not previously been administered. The local irradiation is given immediately prior to TMI administration. Transplant #2 starts sometime between day 60 and 120 after transplant #1. For transplant #2, cohorts of 4 patients are treated with TMI twice a day for 5 days at initial dose level on days -5 through -1. TMI is administered over 30-40 minutes. The second half of the PBSC is infused 1-24 hours following the last dose of TMI. After treatment of at least 4 patients at the initial TMI dose level, dose levels escalate in the absence of toxicity. If there is no dose limiting toxicity (DLT) in the current group of 4 patients, the next cohort is treated at the next higher dose level. If 1 of the 4 patients experiences DLT, the next cohort is treated at the same dose. If 1 DLT is seen among 8 patients treated at a dose, then the next cohort is treated at the next higher dose level. If 2 patients out of 8 experience DLT, this dose is identified as the maximum tolerated dose (MTD). If 1 out of 4 or 3 out 8 patients experience DLT at a dose level, the next lower dose level is identified as the MTD. Each patient in a cohort is observed for a minimum of 28 days prior to escalation to the higher dose level. Tumor restaging occurs approximately 9 months after initial transplant, then at 12 months and annually thereafter.

PROJECTED ACCRUAL: An expected 12-16 patients are required to complete this study. Accrual should last 3-4 years at 4-5 patients per year.
BACKGROUND: Calcaneal osteotomies correct hindfoot deformities and are often performed using a minimally invasive technique. The aim was to compare the safety of three calcaneal osteotomy techniques (oblique, chevron with apex anterior and chevron with apex posterior).
METHODS: Each osteotomy technique was performed on five cadavers (n = 15). These were then dissected to identify any injury to the neurovascular bundles. The distance between the burr and these structures was measured.
RESULTS: Using the apex posterior technique, the burr was closer to the medial and lateral neurovascular structures, and in one case the sural nerve was injured. There were no neurovascular injuries using the other techniques.
CONCLUSIONS: Minimally invasive surgery using a burr is generally a safe, reliable method for performing calcaneal osteotomies. The chevron with apex posterior osteotomy should be performed with caution given the closer relationship between the burr and neurovascular bundles. The other two techniques provide safer alternatives.
Stimulation of target cells using light, e.g., in vivo, is implemented using a variety of methods and devices. In one such device, target cells are stimulated using an implantable device. The device includes a light source for producing light from electrical power. An optical transmission element is made from a material that is substantially transparent to the light from the light light source. This transmission element substantially encases the light source at a proximal end. The transmission element delivers light from the light source to a distal end. The shape and size of the transmission element facilitates implanting of the element within a patient. A fixation portion physically couples to the optical transmission element and secures the device to the patient. A heat dissipation portion removes heat from the near optical transmission element and the light source and dissipates the removed heat through the fixation portion.
Participants who visit content pages on the Mental Health America (MHA) website after completing screening will receive stage 2 randomization into one of three content page conditions. In the embedded single-question Do-It-Yourself (DIY) condition, a single DIY question will be embedded within the content page.
Patients in both groups will then undergo salvage total laryngectomy STL surgery with primary suturing.The primary suture can be performed according to the different techniques available at the discretion of the surgeon (vertical, horizontal or T-shaped closure, with continuous suture, according to Connell or with detached stitches)31. It would be preferable for all centers to use a homogeneous pharyngeal suture technique, such as the T-shaped with Connell suture.
Method comprises (i) drying, and finely grinding the fruit residue after juice extraction; (ii) solvent extracting; and (iii) evaporating the solvent from the extract to leave the oil. The polarity of the solvent is a function of the material being extracted. Extraction is pref. by infusion or percolation. The prod. can be used as such or fractionated to give food grade colourants for use with fruit drinks, bread and bakery prods., in toilet or cosmetic prods. The oil is rich in carotenoid (provitamin A) pigments and tocophenols (vitamin E).
The invention discloses a composition for treating tooth decay. The composition is prepared by uniformly mixing 5 ml of sterile water, 250-500 ml of glucose injection and 0.5-1 g of cyhalothrin, wherein the concentration of the glucose injection is 5-15%. The ratio of the 5 ml of sterile water to 250 ml of 10% glucose injection to 0.5 g of cyhalothrin is standard, and the composition is suitable for being prepared for use immediately. After preparation, the storage time is not longer than 12 months, and preservation is performed on the condition of avoiding sunshine and keeping ambient temperature. When the composition is in use, the composition is shaken up and poured into a cup, an oral cavity is filled with liquid medicine, the upper and lower teeth are clenched, the cheek is plumped up, and liquid medicine repeatedly flows through slits between the teeth, so that the composition acts on tooth bodies sufficiently, each mouthwashing is performed for about 3-5 min, the liquid medicine is spit out immediately after mouthwashing, and rinsing mouthwashing and toothbrush mouthwashing are performed continuously for 2-3 times. According to the composition, pains caused by tooth decay can be rapidly eliminated, the tooth decay pain morbidity can be lowered, the composition cannot be taken orally and will not be absorbed by a digestive system, only mouthwashing is needed, and the composition is safe, reliable, simple in formula, easy to prepare, cheap in raw material source and easy to implement.
At injection sites, localized lipoatrophy and, rarely, injection site skin necrosis may occur. Lipoatrophy occurred in approximately 2% of patients exposed to COPAXONE 20 mg per mL in the 5 placebo-controlled trials compared to none on placebo, and 0.5% of patients exposed to COPAXONE 40 mg per mL in a single placebo-controlled trial and none on placebo. Skin necrosis has only been observed in the postmarketing setting. Lipoatrophy may occur at various times after treatment onset (sometimes after several months) and is thought to be permanent. There is no known therapy for lipoatrophy. To assist in possibly minimizing these events, the patient should be advised to follow proper injection technique and to rotate injection sites with each injection.
This study is designed as a parallel double-blind randomized controlled trial. Patients will be divided into two groups: the Mobilization with Movement Group (MMG) and the Sham Group (SG). The MMG will receive cervical mobilization (SNAG) treatment. The SG, on the other hand, will receive active joint movements without the 'sliding' motion applied to the spinal segment. Prior to and immediately after the intervention, participants will undergo myometric evaluation of neck muscles, joint range of motion measurements, and pressure pain threshold measurements bilaterally, followed by assessment of the individual's pain and level of disability using questionnaires related to pain and pain-associated disability. A 2-minute break will be provided after the intervention before reassessment is conducted. Patients will not be followed up.
The invention discloses PPM1G gene targeted shRNA and application thereof, belonging to the technical field of biological engineering. The PPM1G gene targeted shRNA is short hairpin RNA aiming at a target sequence of the PPM1G gene, and the target sequence is shown as SEQ ID NO. 2. The invention provides a nucleic acid sequence of a small interference fragment PPM1G based on the difficulty faced by colorectal cancer clinical treatment that recurrence and metastasis are easy to occur after treatment. Cytological experiments show that the small interfering RNA provided by the invention has important functions of inhibiting protein expression of colorectal cancer cells PPM1G, inhibiting cancer cell proliferation and migration invasion and increasing radiotherapy sensitivity. Therefore, the invention provides a new technical means for developing a new target for tumor treatment, and the provided PPM1G gene-targeted shRNA has very important application value and prospect for clinical treatment of tumors and targeted drug development.
FIELD: heterocyclic compounds, antibiotics. SUBSTANCE: process is carried out by reaction of benzylpenicillin with potassium acetate in the medium of butylacetate. At the first stage saturated aqueous solution of potassium acetate in the mixture with butylacetate taken at the ratio benzylpenicillin: potassium acetate: acetic acid = 1:(8.8-9.9):(1.6-7.2) is used. At the second stage butylacetate solution of benzylpenicillin is added simultaneously with saturated aqueous potassium acetate solution at their mole ratio 1:[1.1-2.5]. Under these conditions quality of the end product is improved (by optical density value) as well as its activity (1570-1580 U/mg); butanol consumption at the stage of benzylpenicillin potassium salt precipitation is excluded. EFFECT: improved method of preparing.
Compassion based Intervention (ABCT) + Usual specialized treatment in mental health. ABCT consists of 8 weekly groupal sessions of 120 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
Glenohumeral OA accounts for approximately 2-5% of all chronic shoulder pain and may be classified into primary and secondary forms. Primary glenohumeral OA is caused by degenerative joint disease, inflammatory arthropathies, and neuropathic arthropathy secondary to syringomyelia or diabetes. Secondary glenohumeral OA is caused by trauma, postoperative changes after arthroscopy or capulorraphy, and osteonecrosis. Hyaluronic acid is found in synovial joint fluid and has viscoelastic, chondroprotective, and possibly anti-inflammatory properties. It has been shown to increase joint lubrication. Platelet-rich plasma contains growth factors that have been shown to promote tissue regeneration. The aim of this study is to determine whether injections of hyaluronic acid or platelet-rich plasma can be used reliably to decrease pain, restore function, and improve quality of life in patients suffering from glenohumeral OA. Patients will be randomized to receive either an injection of hyaluronic acid or an injection of platelet-rich plasma. Outcomes will be assessed via questionnaires for up to 52 weeks post-procedure.
The present invention relates to a composition of SOD and animal medicines or the extract of the animal medicines, and a preparation method of the composition. The SOD and the animal medicines or the extract of the animal medicines are purified, and the proportioning of the SOD and the animal medicines or the extract of the animal medicines is 1 to 10: 1. the present invention is namely the joint application of the composition of the purified SOD and the purified animal medicines or the extract of the animal medicines, but not the direct application of non-SOD and primitive compound traditional Chinese medicines. The composition of the SOD and the animal medicines or the extract of the animal medicines can enhance the conctntration and the effective components of the medicine, enhance the antioxidative activity by more than 10 times. The skin and mucosa absorption rate reaches more than 90 %, and the half-life is prolonged by more than two orders of magnitude. The composition of the SOD and the animal medicines or the extract of the animal medicines can enter cells to directly exert the function of removing free radicals, and has stronger anti-lipid peroxidation. The comprehensive medicine effect is more thoroughly exerted and is much better than the medicine effect of the traditional compound traditional Chinese medicines. The composition of the SOD and the animal medicines or the extract of the animal medicines is used for enhancing the anti-oxygen deficiency capability, exerting fatigue resistance efficiency and enhancing exercise tolerance, and is a great invention for human medicine careers. The present invention is characterized in that the composition of the SOD and the animal medicines or the extract of the animal medicines is the best way to exert the efficiency of the medicine, is significant contribution to human health careers, and can cause revolution of the materia medica, the biology, the pharmacology and the pharmacodynamics and initiate new.
Glaucoma:

The recommended dosage is 1 capsule (500 mg) two times a day. Usually 1 capsule is administered in the morning and 1 capsule in the evening. It may be necessary to adjust the dose, but it has usually been found that dosage in excess of 2 capsules (1 g) does not produce an increased effect. The dosage should be adjusted with careful individual attention both to symptomatology and intraocular tension. In all cases, continuous supervision by a physician is advisable.

In those unusual instances where adequate control is not obtained by the twice-a-day administration of Acetazolamide Extended-Release Capsules, the desired control may be established by means of Acetazolamide (tablets or parenteral). Use tablets or parenteral in accordance with the more frequent dosage schedules recommended for these dosage forms, such as 250 mg every four hours, or an initial dose of 500 mg followed by 250 mg or 125 mg every four hours, depending on the case in question.

Acute Mountain Sickness: Dosage is 500 mg to 1000 mg daily, in divided doses using tablets or extended-release capsules as appropriate. In circumstances of rapid ascent, such as in rescue or military operations, the higher dose level of 1000 mg is recommended. It is preferable to initiate dosing 24 to 48 hours before ascent and to continue for 48 hours while at high altitude, or longer as necessary to control symptoms.
FIELD: isolation biologically active substances. SUBSTANCE: invention relates to isolation of biologically active substances from vegetable material for production of components of pharmaceutical products and cosmetics. Vegetable raw material, chiefly of amaranth family, is infused with extracting vegetable oil at atmosphere pressure and elevated temperature, said vegetable raw material being green mass or seeds ground to particle size no larger than 5 mm, from which at least 10% are ground to particle size below 0.5 mm, and from said extracting vegetable oil at least one being selected from group including linseed, corn, and soybean oils. Infusion is carried out for at least 10 h at temperature changing from 70 +/- 10 C to 25 +/- 10 C and stirring with speed 60 +/- 40 rpm. EFFECT: increased yield of biologically active substances. 7 cl, 4 ex
The salt-inducible kinases (SIK) 1-3 are key regulators of pro- versus anti-inflammatory cytokine responses during innate immune activation. The lack of highly SIK-family or SIK isoform-selective inhibitors suitable for repeat, oral dosing has limited the study of the optimal SIK isoform selectivity profile for suppressing inflammation in vivo. To overcome this challenge, we devised a structure-based design strategy for developing potent SIK inhibitors that are highly selective against other kinases by engaging two differentiating features of the SIK catalytic site. This effort resulted in SIK1/2-selective probes that inhibit key intracellular proximal signaling events including reducing phosphorylation of the SIK substrate cAMP response element binding protein (CREB) regulated transcription coactivator 3 (CRTC3) as detected with an internally generated phospho-Ser329-CRTC3-specific antibody. These inhibitors also suppress production of pro-inflammatory cytokines while inducing anti-inflammatory interleukin-10 in activated human and murine myeloid cells and in mice following a lipopolysaccharide challenge. Oral dosing of these compounds ameliorates disease in a murine colitis model. These findings define an approach to generate highly selective SIK1/2 inhibitors and establish that targeting these isoforms may be a useful strategy to suppress pathological inflammation.
Kidney diseases represent a global public health problem due to the aging of the population, the increasing prevalence of diabetes, hypertension, obesity and immune disorders. TNF-superfamily ligands are heterotrimeric transmembrane proteins with a molecular structure characterized by the presence of a TNF homology domain that binds to cysteine-rich regions of specific TNF-superfamily receptors. The tumor necrosis factor (TNF) superfamily consists of ligands and receptors that modulate adaptive immunity regulation, hematopoiesis, morphogenesis, as well as different disease states, including cancer and diabetes. DcR3 is found increased in a variety of cancer cells and various inflammatory tissues and is considered a potential biomarker to predict inflammatory disease progression and cancer metastasis. While increasing DcR3 expression may be possible to treat inflammatory diseases and enhance tissue repair, decreasing DcR3 expression may increase tumor apoptosis and suppress tumor growth in vivo. The study will be carried out with the prospective examination of patients without anuria and who developed Acute Kidney Injury or on the basis of Acute Kidney Disease on Chronic Kidney Disease. Sixty patients and 30 age- and gender matched control healthy individuals that accept enrollment in the study will be followed up by the Nephrology Department in Kırıkkale University Faculty of Medicine for 2 years. The aim of this study was to investigate the relationship between blood and urine DcR 3 levels on the effects of renal and patient prognosis in patients with Acute Kidney Injury as a predictor or an auxiliary test in prediction.
<P>PROBLEM TO BE SOLVED: To provide a frizzy hair-correcting method accompanying the reduction of hair keratin, to provide a method for maintaining or recovering the corrected state, and to provide a composition used for the methods.  <P>SOLUTION: This hair-treating method comprises processes A and B, wherein hair is shaped in one or more of the processes. The process A: sequentially applying the hair with a first agent containing a reducing agent and then with a second agent containing an oxidizing agent and having a buffering ability and a pH value of 1 to 5, washing the hair with water and then drying the hair (the first agent or the second agent contains an organic acid (A) or its salt). The process B: sequentially applying the hair with the first agent containing the reducing agent, with an intermediate treating agent having a buffering ability and a pH value of 1 to 5 and then with the second agent containing the oxidizing agent, washing the hair with water and then drying the hair (the first agent or the intermediate treating agent contains the organic acid (A) or its salt). The organic acid (A): a compound which has a 3 to 11C non-aromatic hydrophobic group or a 4 to 18C aromatic hydrophobic group totally containing, and an acid group such as a sulfo group or a sulfonate group. Thereby, an extremely high frizzy hair-correcting effect is obtained by the simple operations of such the extents as those of ordinary straight permanent operations.  <P>COPYRIGHT: (C)2004,JPO
OBJECTIVE: p63 is a transcription factor involved in multiple biological functions. In the liver, the TAp63 isoform induces lipid accumulation in hepatocytes. However, the role of liver TAp63 in the progression of metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis is unknown.
METHODS: We evaluated the hepatic p63 levels in different mouse models of steatohepatitis with fibrosis induced by diet. Next, we used virogenetic approaches to manipulate the expression of TAp63 in adult mice under diet-induced steatohepatitis with fibrosis and characterized the disease condition. Finally, we performed proteomics analysis in mice with overexpression and knockdown of hepatic TAp63.
RESULTS: Levels of TAp63, but not of ΔN isoform, are increased in the liver of mice with diet-induced steatohepatitis with fibrosis. Both preventive and interventional strategies for the knockdown of hepatic TAp63 significantly ameliorated diet-induced steatohepatitis with fibrosis in mice fed a methionine- and choline-deficient diet (MCDD) and choline deficient and high fat diet (CDHFD). The overexpression of hepatic TAp63 in mice aggravated the liver condition in mice fed a CDHFD. Proteomic analysis in the liver of these mice revealed alteration in multiple proteins and pathways, such as oxidative phosphorylation, antioxidant activity, peroxisome function and LDL clearance.
CONCLUSIONS: These results indicate that liver TAp63 plays a critical role in the progression of diet-induced steatohepatitis with fibrosis, and its inhibition ameliorates the disease.